Research progress of DPYD gene variation in colorectal cancer / 肿瘤研究与临床

ABSTRACT

5-fluorouracil (5-Fu) as the most common adjuvant chemotherapy has been widely used for patients with colorectal cancer.As reported dihydropyrimidine dehydrogenase (DPD) has been known as an initial rate-limiting enzyme to catalyze approximately 80 ％ of administered dose of 5-Fu.However,patients with a partial or complete DPD deficiency because of the mutation of DPYD gene may suffer from diarrhea,stomatitis,hand-foot syndrome or neurotoxicity and even death.In this article,the application of DPYD gene screening in patients with colorectal cancer of current status and recent clinical application are reviewed.